Compare SERV & CRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SERV | CRON |
|---|---|---|
| Founded | 2017 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 913.2M | 1.0B |
| IPO Year | N/A | 2015 |
| Metric | SERV | CRON |
|---|---|---|
| Price | $9.08 | $2.53 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $18.60 | N/A |
| AVG Volume (30 Days) | ★ 3.6M | 1.1M |
| Earning Date | 03-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,587,000.00 |
| Revenue This Year | $908.60 | $32.15 |
| Revenue Next Year | $183.94 | $10.45 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 24.63 |
| 52 Week Low | $4.66 | $1.60 |
| 52 Week High | $18.64 | $3.43 |
| Indicator | SERV | CRON |
|---|---|---|
| Relative Strength Index (RSI) | 43.58 | 47.30 |
| Support Level | $8.02 | $2.44 |
| Resistance Level | $11.08 | $2.77 |
| Average True Range (ATR) | 0.59 | 0.08 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 14.58 | 50.91 |
Serve Robotics Inc is developing next-generation robots for last-mile delivery services. It design, develop and operate low-emissions robots on AI-powered robotics mobility platform, that serve people in public spaces, starting with food delivery. Its first product is a zero-emission robot that serves people in public areas, Starting with food delivery. It has developed an AI-robotics mobility platform, with last-mile delivery in cities as its first application.
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.